Section Arrow
TRAW.NASDAQ
- Traws Pharma Inc
Quotes are at least 15-min delayed:2026/07/16 16:14 EDT
After Hours
Last
 0.664
-- (--)
Bid
0.644
Ask
0.6898
High 0.664 
Low 0.664 
Volume
Regular Hours (Closed)
Last
 0.6689
+0.0145 (+2.22%)
Day High 
0.6809 
Prev. Close
0.6544 
1-M High
0.945 
Volume 
93.51K 
Bid
0.644
Ask
0.6898
Day Low
0.65 
Open
0.6767 
1-M Low
0.6455 
Market Cap 
9.97M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.72 
20-SMA 0.78 
50-SMA 1.23 
52-W High 3.265 
52-W Low 0.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.87/-0.57
Enterprise Value
9.97M
Balance Sheet
Book Value Per Share
-0.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.79M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
After Hours 0.14145 -0.00625 -4.23%
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
After Hours 7.1014 -0.0486 -0.68%
KAPAKairos Pharma Ltd.0.34+0.022+6.92%-- 
After Hours 0.3448 -- --
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
After Hours 3.0299 +0.0099 +0.33%
IOVAIovance Biotherapeutics4.655-0.085-1.79%-- 
After Hours 4.66 -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.